Predicting the pathology results of radical prostatectomy from preoperative information: A validation study

Cancer

Volumn 83, Issue 8, 1998, Pages 1567-1580

  Vollmer, Robin T ^a,c   Keetch, David W ^b   Humphrey, Peter A ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DURHAM VA MEDICAL CENTER   (United States)

Author keywords

Modeling; Pathology; Prostate carcinoma; Prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER SCREENING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEEDLE BIOPSY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATECTOMY;

AGED; ALGORITHMS; BIOPSY, NEEDLE; CARCINOMA; DISCRIMINANT ANALYSIS; FORECASTING; HUMANS; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROBABILITY; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 0032531962     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19981015)83:8<1567::AID-CNCR12>3.0.CO;2-E     Document Type: Article

References (33)

1. Epstein JI, Walsh PC, Brendler CB. Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experience with tumors found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C). J Urol 1994;152: 1721-9.
2. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of non-palpable (stage T1c) prostate cancer. JAMA 1994;271:368-74.
3. Dugan JA, Bostwick DG, Myers RP, Qian J, Bergstraih EJ, Oesterling JE. The definition and preoperative prediction of clinically insignificant prostate cancer. JAMA 1996;275:288-94.
4. Terris MK, McNeal JE, Stamey TA. Detection of clinically significant prostate cancer by transrectal ultrasound-guided systematic biopsies. J Urol 1992;148:829-32.
5. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993;150:110-4.
6. Partin AW, Kattan MW, Subong ENP, Walsh PC, Wojno KJ, Oesterling JE, et al. Combination of prostate specific antigen, clinical stage, and Gleason score to predict pathologic stage of localized prostate cancer: a multi-institutional update. JAMA 1997;277:1445-51.
7. Ackerman DA, Barry JM, Wicklund RA, Olson N, Lowe BA. Analysis of risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy. J Urol 1993;150:1845-50.
8. Irwin MB, Trappasso JG. Identification of insignificant prostate cancers: analysis of preoperative parameters. Urology 1994;44:862-8.
9. Dietrick DD, McNeal JE, Stamey TA. Core cancer length in ultrasound-guided systematic sextant biopsies: a preoperative evaluation of prostate cancer volume. Urology 1995;45: 987-92.
10. Cupp MR, Bostwick DG, Myers RP, Oesterling JE. The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. J Urol 1995;153: 1543-8.
11. Terris MK, Haney DJ, Johnstone IM, McNeal JE, Stamey TA. Prediction of prostate cancer volume using prostate-specific antigen levels, transrectal ultrasound, and systematic sextant biopsies. Urology 1995;45:75-80.
12. Peller PA, Young DC, Marmaduke DP, Marsh WL, Badalament RA. Sextant prostate biopsies: a histopathologic correlation with radical prostatectomy specimens. Cancer 1995; 75:530-8.
13. Badalament RA, Miller MC, Peller PA, Young DC, Gahn DK, et al. An algorithm for predicting non-organ-confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level. J Urol 1996;156: 1275-380.
14. Huland H, Hammerer P, Henke R, Huland E. Preoperative prediction of tumor heterogeneity and recurrence after radical prostatectomy for localized prostate carcinoma with digital rectal examination, prostate specific antigen and the results of 6 systematic biopsies. J Urol 1996;155: 1344-7.
15. Ravery V, Schmid H, Toublanc M, Boccon-Gibod L. Is the percentage of cancer in biopsy cores predictive of extracapsular disease in T1-T2 prostate cancer? Cancer 1996; 78:1079-84.
16. Goto Y, Ohori M, Arakawa A, Kattan MW, Wheeler TM, Scardino PT. Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J Urol 1996;156:1059-63.
17. D'Amico AV, Chang H, Holupka E, Renshaw AA, Desjarden A, Chen M, et al. Calculated prostate cancer volume: the optimal predictor of actual cancer volume and pathologic stage. Urology 1997;49:385-91.
18. Bostwick DG, Wheeler TM, Blute M, Barren DM, MacLennan GT, et al. Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Urology 1996;48:47-57.
19. Catalona WJ, Smith DS, Ratiiff TL, Dodds KM, Coplen DE, Yuan JJJ, et al. Measurement of prostate specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156-61.
20. Humphrey PA, Baty J, Keetch D. Relationship between se rum prostate specific antigen, needle biopsy findings, and histopathologic features of prostatic carcinoma in radical prostatectomy tissues. Cancer 1995;75:1842-9.
21. Humphrey PA, Keetch DW, Smith DS, Shepherd DL, Catalona WJ. Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening. J Urol 1996;155:816-20.
22. Gleason DF. Histologic grading of prostate cancer: a perspective. Hum Pathol 1992;23:273-9.
23. Cleveland WS, Grosse E, Shyu WM. Local regression models. In: Chambers JM, Hastie TJ, editors. Statistical models in S. Chapter 8. Pacific Grove: Wadsworth & Brooks/Cole Advanced Books & Software, 1992:314.
24. Chambers JM, Cleveland WS, Kleiner B, Tukey PA. Graphical methods for data analysis. Belmont, CA: Wadsworth, 1983:121-2.
25. Kattan MW, Stapleton AMF, Wheeler TM, Scardino PT. Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma. Cancer 1997;79: 528-37.
26. Vollmer RT. Multivariate statistical analysis for pathologists. Part I: The logistic model. Am J Clin Pathol 1996; 105:115-26.
27. Mccullagh P, Neider JA. Generalized linear models. London: Chapman & Hall, 1989.
28. D'Amico AV, Whittington R, Schnall M, Malkowicz SB, Tomaszewski JE, Schultz D, et al. The impact of the inclusion of endorectal coil magnetic resonance imaging in a multivariate analysis to predict clinically unsuspected extraprostatic tumor. Cancer 1995;75:2368-72.
29. Gomella LG, Raj GV, Moreno JG. Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer. J Urol 1997;158:326-37.
30. Ferrari AC, Stone NN, Eyler JN, Gao M, Mandeli J, Unger P, et al. Prospective analysis of prostate-specific markers in pelvic lymph nodes of patients with high-risk prostate cancer. J Natl Cancer Inst 1997;89:1498-504.
31. Arcangeli CG, Shepherd DL, Smith DS, Humphrey PA, Keetch DW, Catalona WJ. Correlation of percent free PSA with pathologic features of prostatic carcinomas. J Urol 1996;155(Suppl):415A.
32. Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S, Moul JW. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol 1996;156:1511-6.
33. Kallakury BVS, Figge J, Leibovich B, Hwang J, Rifkin M, Kaufman R, et al. Increased bcl-2 protein levels in prostatic adenocarcinomas are not associated with rearrangements in the 2.8 kb major breakpoint region or with p53 protein accumulation. Mod Pathol 1996;9:41-7.